Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
4.56M
-
Number of holders
-
263
-
Total 13F shares, excl. options
-
261M
-
Shares change
-
+5.74M
-
Total reported value, excl. options
-
$1.72B
-
Value change
-
+$28.7M
-
Put/Call ratio
-
1.72
-
Number of buys
-
148
-
Number of sells
-
-97
-
Price
-
$6.59
Significant Holders of RECURSION PHARMACEUTICALS, INC. - Common Stock (RXRX) as of Q3 2024
324 filings reported holding RXRX - RECURSION PHARMACEUTICALS, INC. - Common Stock as of Q3 2024.
RECURSION PHARMACEUTICALS, INC. - Common Stock (RXRX) has 263 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 261M shares
.
Largest 10 shareholders include ARK Investment Management LLC (32.8M shares), BAILLIE GIFFORD & CO (25.2M shares), VANGUARD GROUP INC (24.3M shares), BlackRock, Inc. (20.7M shares), RA CAPITAL MANAGEMENT, L.P. (15.4M shares), Mubadala Investment Co PJSC (13M shares), STATE STREET CORP (12.9M shares), Kinnevik AB (publ) (11.9M shares), Sumitomo Mitsui Trust Group, Inc. (9.77M shares), and Nikko Asset Management Americas, Inc. (9.69M shares).
This table shows the top 263 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.